Companies
Redwire Space
completed on-orbit operations for a cancer therapeutic and other pharmaceutical investigations launched to the International Space Station, and operates a commercial mission program advancing in-space pharmaceutical development.
- Country
- United States
- Ticker
- RDW
Commercial
Coverage
| CN | EU | US | |
|---|---|---|---|
| cross-sector-intersections | ✓ | ✓ | ✓ |
| upstream-bioreactors | ✓ | ✓ | ✓ |
Regulatorsfdafaa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $25 million single award IDIQ contract from NASA (2025-08-28) | rdw.com |
| Funding | $4 million in additional NASA funding (2026-03-11) | rdw.com |
| Production site | 28 locations in North America and Europe (2025-12-31) | ir.rdw.com |
| Production site | 30,000 square foot facility in Georgetown, Indiana (2026-07-21) | rdw.com |
| Headcount | approximately 1,400 employees (2026-07-21) | ir.rdw.com · rdw.com |
| Revenue | $117.1 million for the second quarter of 2026 (2026-06-30) | sec.gov |
| Capacity | 11 active payload facilities on the International Space Station (2025-12-31) | ir.rdw.com |
Independent sources: ir.rdw.com · rdw.com · sec.gov
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| In-space organ bioprinting | cross-sector-intersections | High | → |
| Space bioeconomy | upstream-bioreactors | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.